Understanding and Improving ¹⁸F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer

Figure 5

Images of a 68-year-old male with T3N0M0 prostate cancer. He had undergone radical prostatectomy, bilateral lymph node dissection, and salvage radiation therapy. He was referred for ¹⁸F-fluciclovine imaging with PSA rising to 0.7 ng/mL. The axial, fused PET/CT image on the left identifies a focus of enhanced ¹⁸F-fluciclovine uptake (white arrow) in the presacral region. The corresponding CT image on the right identifies a 6-mm lymph node metastasis (yellow arrow).